Search

Your search keyword '"John McClean"' showing total 8 results
Start Over Author "John McClean" Publication Year Range Last 10 years
8 results on '"John McClean"'

2. Family and the Mission of God

Author

John McClean

Abstract

This article considers the question: to what extent and in what ways is ‘family’ part of God’s work (that is his mission). It argues that family is foundational for God’s pattern in creation and key to the life of Israel, but in both cases is the basis for other institutions. God’s mission is accomplished through the birth of the Christ into a family in Israel and he is the start of the new humanity, given within Israel. The coming of Christ reconfigures family relationships, restores family and recruits it for his mission. On the basis of this survey several implications for Christian life and ministry are outlined.

Published
2022
Full Text
View/download PDF

3. First Sounds from Mars

Author

sylvestre Maurice, Baptiste Chide, Naomi Murdoch, Ralph Lorenz, David Mimoun, Roger Wiens, Alexander Stott, Xavier Jacob, Tanguy Bertrand, Franck Montmessin, Nina Lanza, Cesar Alvarez Llamas, S. M. Angel, M. Aung, J. Balaram, Olivier Beyssac, Agnès Cousin, Greg Delory, Olivier Forni, Thierry Fouchet, Olivier Gasnault, Havard Grip, Mike hecht, Jeff Hoffman, Javier Laserna, Jérémie Lasue, Justin Maki, John McClean, Pierre-Yves Meslin, Stéphane Le Mouélic, Asier Munguira, Claire Newman, Jose Rodriguez-Manfredi, Javier Moros, Paolo Pilleri, Susanne Schroeder, Manuel de la Torre, Ann Ollila, Thoedore Tzanetos, Ken Farley, Kathryn Stack, and Ken Williford

Abstract

The authors have requested that this preprint be removed from Research Square.

Published
2021
Full Text
View/download PDF

4. A Modest Increase in 11C-PK11195-Positron Emission Tomography TSPO Binding in Depression Is Not Associated With Serum C-Reactive Protein or Body Mass Index

Author

Julia J. Schubert, Mattia Veronese, Tim D. Fryer, Roido Manavaki, Manfred G. Kitzbichler, Maria A. Nettis, Valeria Mondelli, Carmine M. Pariante, Edward T. Bullmore, Federico E. Turkheimer, Dominika Wlazly, Amber Dickinson, Andy Foster, Clare Knight, Claire Leckey, Paul Morgan, Angharad Morgan, Caroline O'Hagan, Samuel Touchard, Shahid Khan, Phil Murphy, Christine Parker, Jai Patel, Jill Richardson, Paul Acton, Nigel Austin, Anindya Bhattacharya, Nick Carruthers, Peter de Boer, Wayne Drevets, John Isaac, Declan Jones, John Kemp, Hartmuth Kolb, Jeff Nye, Gayle Wittenberg, Gareth Barker, Anna Bogdanova, Heidi Byrom, Diana Cash, Annamaria Cattaneo, Daniela Enache, Tony Gee, Caitlin Hastings, Melisa Kose, Giulia Lombardo, Nicole Mariani, Anna McLaughlin, Maria Nettis, Naghmeh Nikkheslat, Carmine Pariante, Karen Randall, Julia Schubert, Luca Sforzini, Hannah Sheridan, Camilla Simmons, Nisha Singh, Federico Turkheimer, Vicky Van Loo, Marta Vicente Rodriguez, Toby Wood, Courtney Worrell, Zuzanna Zajkowska, Brian Campbell, Jan Egebjerg, Hans Eriksson, Francois Gastambide, Karen Husted Adams, Ross Jeggo, Thomas Moeller, Bob Nelson, Niels Plath, Christian Thomsen, Jan Torleif Pederson, Stevin Zorn, Catherine Deith, Scott Farmer, John McClean, Andrew McPherson, Nagore Penandes, Paul Scouller, Murray Sutherland, Mary Jane Attenburrow, Jithen Benjamin, Helen Jones, Fran Mada, Akintayo Oladejo, Katy Smith, Rita Balice-Gordon, Brendon Binneman, James Duerr, Terence Fullerton, Veeru Goli, Zoe Hughes, Justin Piro, Tarek Samad, Jonathan Sporn, Liz Hoskins, Charmaine Kohn, Lauren Wilcock, Franklin Aigbirhio, Junaid Bhatti, Ed Bullmore, Sam Chamberlain, Marta Correia, Anna Crofts, Tim Fryer, Martin Graves, Alex Hatton, Manfred Kitzbichler, Mary-Ellen Lynall, Christina Maurice, Ciara O'Donnell, Linda Pointon, Peter St George Hyslop, Lorinda Turner, Petra Vertes, Barry Widmer, Guy Williams, Jonathan Cavanagh, Alison McColl, Robin Shaw, Erik Boddeke, Alison Baird, Stuart Clare, Phil Cowen, I-Shu (Dante) Huang, Sam Hurley, Simon Lovestone, Alejo Nevado-Holgado, Elena Ribe, Anviti Vyas, Laura Winchester, Madeleine Cleal, Diego Gomez-Nicola, Renzo Mancuso, Hugh Perry, Mara Cercignani, Charlotte Clarke, Alessandro Colasanti, Neil Harrison, Rosemary Murray, Jason O'Connor, and Howard Mount

Subjects
medicine.medical_specialty, Cognitive Neuroscience, 050105 experimental psychology, Body Mass Index, C-reactive protein, Pathogenesis, 03 medical and health sciences, 0302 clinical medicine, Receptors, GABA, Interquartile range, Internal medicine, medicine, Translocator protein, Humans, 0501 psychology and cognitive sciences, Radiology, Nuclear Medicine and imaging, Prefrontal cortex, Biological Psychiatry, Anterior cingulate cortex, Inflammation, Depressive Disorder, Major, biology, business.industry, Depression, 05 social sciences, Microglia, PET, TSPO, medicine.disease, Isoquinolines, Archival Report, Endocrinology, medicine.anatomical_structure, Positron-Emission Tomography, biology.protein, Major depressive disorder, Neurology (clinical), business, Body mass index, 030217 neurology & neurosurgery
Abstract

Background: Immune mechanisms have been implicated in the pathogenesis of depression. Translocator protein (TSPO)–targeted positron emission tomography (PET) has been used to assess neuroinflammation in major depressive disorder. We aimed to 1) test the hypothesis of significant case-control differences in TSPO binding in the anterior cingulate cortex, prefrontal cortex, and insula regions; and 2) explore the relationship between cerebral TSPO binding and peripheral blood C-reactive protein (CRP) concentration. Methods: A total of 51 depressed subjects with Hamilton Depression Rating Scale score >13 (median 17; interquartile range, 16–22) and 25 healthy control subjects underwent dynamic brain 11C-PK11195 PET and peripheral blood immune marker characterization. Depressed subjects were divided into high CRP (>3 mg/L; n = 20) and low CRP (2 p = .09; F 1,71 = 6.97, p = .01), which was not influenced by body mass index. The case-control difference was greatest in the anterior cingulate cortex (d = 0.49; t 74 = 2.00, p = .03) and not significant in the prefrontal cortex or insula (d = 0.27 and d = 0.36, respectively). Following CRP stratification, significantly higher TSPO binding was observed in low-CRP depression compared with controls (d = 0.53; t 54 = 1.96, p = .03). These effect sizes are comparable to prior major depressive disorder case-control TSPO PET data. No significant correlations were observed between TSPO and CRP measures. Conclusions: Consistent with previous findings, there is a modest increase in TSPO binding in depressed patients compared with healthy control subjects. The lack of a significant correlation between brain TSPO binding and blood CRP concentration or body mass index poses questions about the interactions between central and peripheral immune responses in the pathogenesis of depression.

Published
2021

5. Photogeologic Map of the Perseverance Rover Field Site in Jezero Crater Constructed by the Mars 2020 Science Team

Author

Kathryn M. Stack, Nathan R. Williams, Fred Calef, Vivian Z. Sun, Kenneth H. Williford, Kenneth A. Farley, Sigurd Eide, David Flannery, Cory Hughes, Samantha R. Jacob, Linda C. Kah, Forrest Meyen, Antonio Molina, Cathy Quantin Nataf, Melissa Rice, Patrick Russell, Eva Scheller, Christina H. Seeger, William J. Abbey, Jacob B. Adler, Hans Amundsen, Ryan B. Anderson, Stanley M. Angel, Gorka Arana, James Atkins, Megan Barrington, Tor Berger, Rose Borden, Beau Boring, Adrian Brown, Brandi L. Carrier, Pamela Conrad, Henning Dypvik, Sarah A. Fagents, Zachary E. Gallegos, Brad Garczynski, Keenan Golder, Felipe Gomez, Yulia Goreva, Sanjeev Gupta, Svein-Erik Hamran, Taryn Hicks, Eric D. Hinterman, Briony N. Horgan, Joel Hurowitz, Jeffrey R. Johnson, Jeremie Lasue, Rachel E. Kronyak, Yang Liu, Juan Manuel Madariaga, Nicolas Mangold, John McClean, Noah Miklusicak, Daniel Nunes, Corrine Rojas, Kirby Runyon, Nicole Schmitz, Noel Scudder, Emily Shaver, Jason SooHoo, Russell Spaulding, Evan Stanish, Leslie K. Tamppari, Michael M. Tice, Nathalie Turenne, Peter A. Willis, R. Aileen Yingst, Unidad de Excelencia Científica Centro de Astrobiología María de Maeztu del Instituto Nacional de Técnica Aeroespacial y CSIC, MDM-2017-0737, Molina, A. [0000-0002-5038-2022], Hughes, C. [0000-0002-7061-1443], Jacob, S. [0000-0001-9950-1486], Arana, Gorka [0000-0001-7854-855X], Sun, V. Z. [0000-0003-1480-7369], Stack, K. [0000-0003-3444-6695], Williford, K. [0000-0003-0633-408X], Flannery, D. [0000-0001-8982-496X], Gupta, S. [0000-0001-6415-1332], Williams, N. [0000-0003-0602-484X], European Research Council (ERC), and National Aeronautics and Space Administration (NASA)

Subjects
010504 meteorology & atmospheric sciences, Mars, Fluvial, Perseverance, 01 natural sciences, Article, Impact crater, 0103 physical sciences, Rover, Impact structure, Digital elevation model, 010303 astronomy & astrophysics, Geomorphology, 0105 earth and related environmental sciences, geography, geography.geographical_feature_category, Bedrock, Astronomy and Astrophysics, Jezero, Mars Exploration Program, 15. Life on land, Geologic map, Planetary science, Space and Planetary Science, Geologic mapping, Geology
Abstract

Stack, K. et al., The Mars 2020 Perseverance rover landing site is located within Jezero crater, a ∼50km diameter impact crater interpreted to be a Noachian-aged lake basin inside the western edge of the Isidis impact structure. Jezero hosts remnants of a fluvial delta, inlet and outlet valleys, and infill deposits containing diverse carbonate, mafic, and hydrated minerals. Prior to the launch of the Mars 2020 mission, members of the Science Team collaborated to produce a photogeologic map of the Perseverance landing site in Jezero crater. Mapping was performed at a 1:5000 digital map scale using a 25 cm/pixel High Resolution Imaging Science Experiment (HiRISE) orthoimage mosaic base map and a 1 m/pixel HiRISE stereo digital terrain model. Mapped bedrock and surficial units were distinguished by differences in relative brightness, tone, topography, surface texture, and apparent roughness. Mapped bedrock units are generally consistent with those identified in previously published mapping efforts, but this study’s map includes the distribution of surficial deposits and sub-units of the Jezero delta at a higher level of detail than previous studies. This study considers four possible unit correlations to explain the relative age relationships of major units within the map area. Unit correlations include previously published interpretations as well as those that consider more complex interfingering relationships and alternative relative age relationships. The photogeologic map presented here is the foundation for scientific hypothesis development and strategic planning for Perseverance’s exploration of Jezero crater., With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (MDM-2017-0737)

Published
2020

6. A Comodulation Analysis of Atmospheric Energy Injection into the Ground Motion at InSight, Mars

Author

Constantinos Charalambous, Alexander E Stott, Tom Pike, John McClean, Tristram Warren, Aymeric Spiga, Donald Banfield, Raphaël F. Garcia, John Clinton, Simon C. Stähler, Sara Navarro López, Philippe Henri Lognonné, Taichi Kawamura, Martin van Driel, Maren Böse, Savas Ceylan, Amir Khan, Anna Catherine Horleston, Guénolé Orhand-Mainsant, Luis Mora Sotomayor, Naomi Murdoch, Domenico Giardini, and William Bruce Banerdt

Published
2020
Full Text
View/download PDF

7. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Author

Judith Trotman, Sally F Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter R Fingerle-Rowson, Jiawen Zhu, Tina Nielsen, Deniz Sahin, Wolfgang Hiddemann, Robert E Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van eygen, Randeep Sangha, Pam Mckay, Jonathan Wilson, Richard Van Der Jagt, Daryl Roitman, Marek Trneny, Jiri Mayer, Katell Le Du, Philippe Solal-Celigny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange-Krex, Axel Florschütz, Hans-Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Hess, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling-Kaiser, Martin Hoffmann, Zita Borbenyi, Miklos Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Parraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, Jose Antonio Marquez Navarro, Carlos Grande Garcia, Herman Nilsson-Ehle, Helen Mccarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin Dyer, Ruth Pettengell, John Seymour, John Gribben, Saad Al-Ismail, Faris Al-Refaie, Norbert Blesing, Christopher Macnamara, Ann O'callaghan, Andrew Haynes, George Follows, Roderick Johnson, David Cunningham, Kristian Bowles, Graham Collins, Eve Gallop-Evans, Stephen Robinson, Chezhian Subash, James Bailey, Viran Holden, Jeffrey Neidhart, Moacyr De Oliveira, Haluk Tezcan, Kevin Kim, Suman Kambhampati, Keith Lanier, John Mcclean, Kensei Tobinai, Kiyohiko Hatake, Michinori Ogura, Toshiki Uchida, Kiyoshi Ando, Tomohiro Kinoshita, Thomas Höhler, Heribert Stauder, Andreas Kirsch, Michael Koenigsmann, Stephan Kremers, Thomas Illmer, Mathias Witzens-Harig, Paul La Roseé, Jan Dürig, Michael Kneba, Manfred Hensel, Stefan Fuxius, Lothar Bergmann, Kai Hübel, Christian Buske, Reinhard Marks, Gerald Wulf, Christian Lerchenmueller, Rudolf Schmits, Mark Reinwald, Eva Lengfelder, Fiona Scott, Takaaki Chou, Masafumi Taniwaki, Isao Yoshida, Kenichi Ishizawa, Naokuni Uike, Nobuhiko Uoshima, Yuri Kamitsuji, Shinsuke Iida, Ken Ohmine, Kisato Nosaka, Kazuhiko Ide, Takayuki Ishikawa, Pierre Desjardins, Nicholas Finn, Jun Zhu, Wei Li, Li Yu, Hanyun Ren, Yuan Kai Shi, Gang Wu, Xiaonan Hong, Qingyuan Zhang, Jifeng Feng, Rong Zhan, Tongyu Lin, Sirpa Leppa, Regis Costello, Adrian Tempescul, Laurence Sanhes, Olivier Tournilhac, Heinz Kirchen, Holger Hebart, Rudolf Weide, Kathleen Jentsch-Ullrich, Irit Avivi, Arnon Nagler, Ronit Gurion, Ofer Shpilberg, Pietro Leoni, Luca Baldini, Olga Samoylova, Alexandr Myasnikov, Tran-Der Tan, Hung Chang, Kyoya Kumagai, Norifumi Tsukamoto, Kunihiro Tsukasaki, Patrick Beatty, Noriko Usui, Koji Izutsu, Tohru Murayama, Tatsuo Ichinohe, Kohmei Kubo, Fumihiro Ishida, J. Thaddeus Beck, Frank Griesinger, Dzhelil Osmanov, Shaker Dakhil, Aline Clavert, Dai Maruyama, Yasuhito Terui, Kazuhito Yamamoto, Ekkehard Eigendorff, Tsutomu Kobayashi, Satoshi Ichikawa, Ilseung Choi, Katsuya Wada, Yoshitaka Kikukawa, Masao Matsuoka, Takayuki Yoshino, Yosuke Minami, Dürig, Jan (Beitragende*r), The University of Sydney, Service de médecine nucléaire [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Prince of Wales Medical Research Institute, University of New South Wales [Sydney] (UNSW), University of Melbourne, Universiteit Gent = Ghent University [Belgium] (UGENT), Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Semmelweis University of Medicine [Budapest], Queens Elizabeth Hospital [Birmingham], Queen Mary University of London (QMUL), IBM Thomas J. Watson Research Center, IBM, Department of Computing and Information Systems, and Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM)

Subjects
Male, Time Factors, [SDV]Life Sciences [q-bio], Follicular lymphoma, Medizin, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Agents, Immunological, Obinutuzumab, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Lymphoma, Follicular, Randomized Controlled Trials as Topic, education.field_of_study, Manchester Cancer Research Centre, Hazard ratio, Middle Aged, Progression-Free Survival, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Female, Immunotherapy, Rituximab, medicine.drug, Bendamustine, medicine.medical_specialty, Population, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Predictive Value of Tests, Internal medicine, medicine, Humans, Progression-free survival, education, Aged, Neoplasm Staging, Retrospective Studies, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, medicine.disease, chemistry, Clinical Trials, Phase III as Topic, Positron-Emission Tomography, business, Tomography, X-Ray Computed, Progressive disease, 030215 immunology
Abstract

BACKGROUND: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET-CT responses after first-line immunochemotherapy in the GALLIUM study.METHODS: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1-3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968.FINDINGS: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6-69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0-79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2-51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9-90·8) in PET complete responders and 72·0% (63·1-79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3-0·6, pINTERPRETATION: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed.FUNDING: F Hoffmann-La Roche.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results